Funding Rounds
Adcendo

Adcendo Series A (2024, $17M)

Adcendo

Antibody-drug conjugates (ADCs) developer for the treatment of cancer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series A

Raised Amount: $17.36M

Investors